Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2
- 29 April 2020
- journal article
- letter
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (2), 188
- https://doi.org/10.1002/cpt.1877
Abstract
We read with a great interest the paper by Du et Chen suggesting dosing regimen of favipiravir in COVID‐191. We would like to complement their observations with our PK/PD experience of favipiravir against Ebola virus (EBOV). The drug EC50 against EBOV and SARS‐CoV‐2 are 10‐60 µg/ml and 9.4 µg/ml4, respectively. However results obtained by our working group suggest a higher value of EC50, in the range 40‐80 µg/ml (X. de Lamballerie & F. Touret, unpublished results). We therefore use the conservative assumption that the drug EC50 against SARS‐CoV‐2 is in the same range as against EBOV.Keywords
This publication has 5 references indexed in Scilit:
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV InfectionClinical Pharmacology & Therapeutics, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaquesPLoS Medicine, 2018
- Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targetedPLoS Neglected Tropical Diseases, 2017
- Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaPLoS Medicine, 2016